These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7895463)

  • 61. Gliclazide treatment lowers serum ICAM-1 levels in poorly controlled type 2 diabetic patients.
    Papanas N; Tziakas D; Chalikias G; Floros D; Trypsianis G; Papadopoulou E; Kortsaris A; Symeonidis G; Souliou E; Maltezos E; Hatseras D
    Diabetes Metab; 2006 Sep; 32(4):344-9. PubMed ID: 16977262
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lack of weight gain with gliclazide treatment for 30 months in type II diabetes.
    Robb GH; Lowe SM
    Curr Med Res Opin; 1984; 9(1):7-9. PubMed ID: 6723350
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Gliclazide on long-term therapy increases insulin response to glucose of type II diabetics.
    Couturier E
    Diabetes Res Clin Pract; 1985-1986 Mar; 1(6):343-7. PubMed ID: 3915271
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Effects of gliclazide and glibenclamide on platelet function, fibrinolysis and metabolic control in diabetic patients with retinopathy (author's transl)].
    Chan TK; Chan V; Teng CS; Yeung RT
    Sem Hop; 1982 May; 58(19):1197-200. PubMed ID: 6285503
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Glibenclamide-associated hypoglycaemia: a report on 57 cases.
    Asplund K; Wiholm BE; Lithner F
    Diabetologia; 1983 Jun; 24(6):412-7. PubMed ID: 6411511
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients.
    Zeng W; Guo Y; Chen P; Liu Z; Chen D; Han C
    J Diabetes Investig; 2016 Sep; 7(5):764-8. PubMed ID: 27181593
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry.
    Yang X; So WY; Ma RC; Yu LW; Ko GT; Kong AP; Ng VW; Luk AO; Ozaki R; Tong PC; Chow CC; Chan JC
    Diabetes Res Clin Pract; 2010 Dec; 90(3):343-51. PubMed ID: 20889221
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect on platelet adhesiveness in diabetics after long-term treatment with a new oral hypoglycaemic agent, gliclazide.
    Rubinjoni Z; Turk Z; Coce F; Mustovic D; Maitre D; Skrabalo Z
    Curr Med Res Opin; 1978; 5(8):625-31. PubMed ID: 361347
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The mode of action and clinical pharmacology of gliclazide: a review.
    Campbell DB; Lavielle R; Nathan C
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S21-36. PubMed ID: 1794262
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The potential of gliclazide, a sulphonylurea to influence the oxidative processes within the pathogenesis of diabetic vascular disease.
    Jennings PE
    Adv Exp Med Biol; 1994; 366():313-24. PubMed ID: 7771262
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Optimal dosing of gliclazide-A model-based approach.
    Mim SR; Hussein H; Vidadi S; Leisegang R; Karamchand S; Rambiritch V; Cotton MF; Naidoo P; Kjellsson MC
    Basic Clin Pharmacol Toxicol; 2023 Jul; 133(1):59-72. PubMed ID: 36999176
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hyperglycaemic clamp and insulin binding to isolated monocytes before and after glibenclamide treatment of mild type II diabetics.
    Pagano G; Lombardi A; Pisu E; Bozzo C; Masciola P; Ferraris GM; Bruno A
    Horm Metab Res; 1984 May; 16(5):215-20. PubMed ID: 6429023
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A case of severe relapsing sulphonylurea-induced hypoglycaemia.
    Mifsud S; Schembri EL; Fava S
    BMJ Case Rep; 2019 Dec; 12(12):. PubMed ID: 31796456
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register.
    Lim LL; Lau ESH; Cheung JTK; Chan SP; Ji L; Lim S; Sirinvaravong S; Unnikrishnan AG; Luk AOY; Cortese V; Durocher A; Chan JCN
    Diabetes Obes Metab; 2023 Jan; 25(1):208-221. PubMed ID: 36082513
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Massive glibenclamide overdose without hypoglycaemia in a man with diabetes after partial pancreatectomy.
    Ferner RE; Alberti KG; Rawlins MD
    Hum Toxicol; 1986 Jul; 5(4):283-4. PubMed ID: 3089912
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gliclazide-induced acute hepatitis.
    Dourakis SP; Tzemanakis E; Sinani C; Kafiri G; Hadziyannis SJ
    Eur J Gastroenterol Hepatol; 2000 Jan; 12(1):119-21. PubMed ID: 10656221
    [TBL] [Abstract][Full Text] [Related]  

  • 77. ADVANCE in context: The benefits, risks and feasibility of providing intensive glycaemic control based on gliclazide modified release.
    Zoungas S
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 2():5-11. PubMed ID: 32250522
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Is Gliclazide Associated with a Lower Obesity-Related Cancer Risk Compared to Other Sulfonylureas? A Long-term Prospective Cohort Study.
    Du J; Kleefstra N; Schrijnders D; Groenier KH; de Bock GH; Landman GWD
    Cancer Epidemiol Biomarkers Prev; 2020 Aug; 29(8):1596-1605. PubMed ID: 32404443
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Diabetes in the elderly.
    Meneilly GS; Tessier D
    Diabet Med; 1995 Nov; 12(11):949-60. PubMed ID: 8582126
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Unexplained severe hypoglycaemia in hospital: a difficult diagnostic challenge.
    Walker J; White R; Vale A; Elliott S; Wass J; Reynolds J
    Br J Clin Pharmacol; 2009 Feb; 67(2):266-7. PubMed ID: 19220272
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.